SINOVAC's Vital Role in the Belt and Road Initiative: A Lifeline in the Fight Against Infectious Diseases
October 20, 2023, Beijing, China – Sinovac Biotech Ltd. ("SINOVAC" or the "Company") (NASDAQ: SVA), a leading provider of biopharmaceutical products in China, today shared its accomplishments in collaboration with the Belt and Road Initiative (BRI) countries, demonstrating its commitment to the initiative's guiding principle of "planning together, building together, and benefiting together."
SINOVAC has provided over 1.2 billion doses of vaccines to 62 BRI countries, offering protection against a range of infectious diseases such as COVID-19, hepatitis A, influenza and varicella, as well as pneumococcal infections.
Behind these remarkable figures are 20 research projects in 10 BRI countries, 95 marketing approvals and emergency use authorizations, 17 technology licensing agreements for vaccine production signed in 12 BRI countries, and localized production programs in seven.
Mr. Weidong Yin, Chairman, President, and CEO of SINOVAC, believes that the BRI offers a broad platform for greater product circulation and cooperation. Within this context, SINOVAC's vaccines can reach and benefit a wider range of countries. Moreover, SINOVAC has the opportunity to make foreign investments, establish joint ventures, engage in research and production partnerships, and foster the development of high-quality vaccines and other biopharmaceutical products under the BRI framework.
During the recent opening ceremony of the Third Belt and Road International Cooperation Summit, Chinese President Xi Jinping emphasized how the Belt and Road became a "life-saving road" as China provided more than 10 billion masks and 2.3 billion doses of vaccine, as well as jointly produced vaccines with over 20 countries. SINOVAC's inactivated COVID-19 vaccine, CoronaVac®, has significantly contributed to these achievements.
There have been more than 700 academic research papers published globally related to CoronaVac®, with the majority of results arising from SINOVAC's collaboration with BRI nations. SINOVAC’s strong global partnerships, particularly with BRI countries like Indonesia, Turkey, Chile, and South Africa, paved the way for accelerating the vaccine’s Phase III clinical trials. Research results verified the vaccine's safety and effectiveness, and more than 60 countries and regions granted emergency use approvals for CoronaVac®, including the World Health Organization's (WHO) Emergency Use Listing (EUL) Procedure.
SINOVAC's cooperation and achievements with BRI countries extend beyond COVID-19. With a mission to supply vaccines to eliminate human diseases, SINOVAC has helped prevent and control infectious diseases in BRI nations and across the globe with its high-quality vaccine products for over a decade. The Company's efforts aim to enhance the accessibility and affordability of these essential public health resources in BRI countries.
Empowering Local Vaccine Production and R&D
As it works to make vaccines more accessible, SINOVAC has entered into 17 technology licensing agreements for vaccine production in 12 countries, providing essential training and expertise to local talent.
In Turkey, SINOVAC and its local partner have built a formulation and packaging facility that will further enhance Turkey's vaccine production capacity. In Egypt, SINOVAC's state-of-the-art automated storage center, which is currently the largest vaccine storage facility in Africa, will significantly boost Egypt's cold chain vaccine storage and distribution capabilities, consequently improving the vaccine supply chain across the African region.
In many BRI nations, SINOVAC has actively engaged in the R&D, production, and import of non-vaccine bioproducts and medical products. These efforts help local governments ensure stable supplies, ultimately allowing more people living in the BRI countries to benefit from China's advancements in life-science technology.
Building a Better, More Sustainable World
SINOVAC actively fulfills its corporate social responsibility in BRI countries. The Company supports local disaster relief efforts, including earthquake and flood relief, underscoring its commitment to the wellbeing of its employees and communities.
Sinovac Biotech Ltd. (SINOVAC) is a China-based biopharmaceutical company that focuses on the R&D, manufacturing, and commercialization of biomedical products that protect against human diseases.
SINOVAC's product portfolio includes vaccines against COVID-19, enterovirus 71 (EV71) infected hand-foot-mouth disease (HFMD), hepatitis A, varicella, influenza, poliomyelitis, pneumococcal disease, mumps, etc.
The COVID-19 vaccine, CoronaVac®, has been approved for use in more than 60 countries and regions worldwide. The hepatitis A vaccine, Healive®, passed WHO prequalification requirements in 2017. The EV71 vaccine, Inlive®, is an innovative vaccine under "Category 1 Preventative Biological Products" and commercialized in China in 2016. In 2022, SINOVAC's Sabin-strain inactivated polio vaccine (sIPV) and varicella vaccine were prequalified by the WHO.
SINOVAC was the first company to be granted approval for its H1N1 influenza vaccine Panflu.1®, which has supplied the Chinese government's vaccination campaign and stockpiling program. The Company is also the only supplier of the H5N1 pandemic influenza vaccine, Panflu®, to the Chinese government stockpiling program.
SINOVAC continually dedicates itself to pipeline development including but not limited to new technology, new vaccines as well as other biomedical products. We will constantly explore global opportunities of strategic expansion.
For more information, please visit the Company’s website at www.sinovac.com.
Sinovac Biotech Ltd.